Chinese Journal of Cancer Research

Papers
(The H4-Index of Chinese Journal of Cancer Research is 15. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Molecular features of gastroenteropancreatic neuroendocrine carcinoma: A comparative analysis with lung neuroendocrine carcinoma and digestive adenocarcinomas58
Efficacy and safety of low-dose cyclophosphamide combined with lenvatinib, pembrolizumab and TACE for unresectable hepatocellular carcinoma: A single-center, prospective, single-arm clinical trial49
Gastric cancer surgery in South Korea: Past, present, and future34
Efficacy of ctDNA methylation combined with traditional detection modality to detect liver cancer among high-risk patients: A multicenter diagnostic trial34
Transforming cancer cells for long-term living with cancer: An inspiring new approach33
Pathogenic germline variants in mismatch repair genes in patients with microsatellite instability-high gastric cancer32
Focal ablation therapy presents promising results for selectively localized prostate cancer patients30
Heterogeneity of tumor-infiltrating myeloid cells in era of single-cell genomics29
Clinical and molecular significance of homologous recombination deficiency positive non-small cell lung cancer in Chinese population: An integrated genomic and transcriptional analysis28
National guidelines for diagnosis and treatment of thyroid cancer 2022 in China (English version)23
Microbiota and urinary tumor immunity: Mechanisms, therapeutic implications, and future perspectives23
Mn-based cGAS-STING activation for tumor therapy23
Detection and classification of breast lesions using multiple information on contrast-enhanced mammography by a multiprocess deep-learning system: A multicenter study23
Tislelizumab in previously treated, locally advanced unresectable/metastatic microsatellite instability-high/mismatch repair-deficient solid tumors22
Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A20
Prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery: Final results of a phase II trial15
0.29691219329834